We are Skolkovo resident academic startup developing and commercializing novel cancer immunotherapies originating from prof. Hiroshi Shiku laboratory at Mie University in Japan.
Prof. Shiku`s laboratory promote global academic consortium aligning leading immunology research and development organizations from Japan, Russia, Brasil and China.
Novo T Cellsk supports an academic translational research and leads commercialization in Russia and beyond.
We offer CAR-T cell therapy not only for "liquid" but also for "solid" tumors at affordable price by localizing automatic cell production at the treatment site.
Cure all cancers one by one.
Bring value to the current and contribute to the next academic innovation
Meet expectations of medical practitioners for innovation
Always think of patients demanding such innovation
Project Assistant Professor, Graduate School of Medicine, Mie University
Global Finance Manager, Arysta LifeSciences Corporation;
M.B.A., Hitotsubashi University (Darden Business School Exchange Program)
Medical Director and Co-Founder, Diamed Private Clinic Group, Ph.D., Doctor of Medicine
Knowledgeable and passionate CSO wanted
Scientific Advisory Board
Professor, Graduate School of Medicine, Mie University, Center for Comprehensive Cancer Immunotherapy.
Ph.D., Doctor of Medicine, Nagoya University School of Medicine
World and Japan leading oncoimminology laboratory, which has been successfully promoting high level research to the global innovation frontier for decades while cooperating with leading industry partners as well as public institutions.
Research Institute of Fundamental and Clinical Immunology
Research Institute of Fundamental and Clinical Immunology is the only Russian academic immunology institution which carries out basic research in the sphere of clinical and experimental immunology on the basis of which the Hospital of Immunology was created. The Hospital includes 5 units and Interregional Center of Marrow Transplantation. Institute developes new cell therapies including CAR-T.